SBIR: Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease

Grants and Contracts Details

StatusActive
Effective start/end date9/1/238/31/24

Funding

  • Gismo Therapeutics Incorporated: $145,527.00